Chawla Lakhmir S
Department of Medicine, Veterans Affairs Medical Center, 3550 La Jolla Village Drive, San Diego, CA, USA.
Intensive Care Med Exp. 2025 Sep 12;13(1):94. doi: 10.1186/s40635-025-00798-w.
Molecular hydrogen gas (HG), administered through inhalation or as hydrogen-rich fluids (HRF), has demonstrated antioxidant, anti-inflammatory, antiapoptotic, cytoprotective, and beneficial mitochondrial effects in critical illness. Preclinical studies and human clinical studies consistently endorse hydrogen gas as safe, with mechanisms of action linked to vital molecular pathways, such as reductions in both oxidative stress and inflammation with beneficial effects on mitochondria. In preclinical studies, HG has been shown to improve outcomes in conditions such as sepsis, acute lung injury, hepatic injury, pancreatitis, cardiac arrest, traumatic injury, acute kidney injury, and brain injury. HG has been given to human subjects across multiple disease states and has a good safety profile with encouraging clinical effects. Given its accessibility, safety, and low-cost, hydrogen gas therapy should be assessed in adequately powered clinical trials in critical illness.
通过吸入或作为富氢液体（HRF）给予的分子氢气（HG），已在危重病中表现出抗氧化、抗炎、抗凋亡、细胞保护和有益的线粒体效应。临床前研究和人体临床研究一致认可氢气是安全的，其作用机制与重要分子途径相关，例如减轻氧化应激和炎症，并对线粒体产生有益影响。在临床前研究中，HG已被证明可改善脓毒症、急性肺损伤、肝损伤、胰腺炎、心脏骤停、创伤性损伤、急性肾损伤和脑损伤等病症的预后。HG已应用于多种疾病状态的人体受试者，具有良好的安全性和令人鼓舞的临床效果。鉴于其可及性、安全性和低成本，应在充分有力的危重病临床试验中评估氢气疗法。
